The role of the glucagon‐FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition
Our findings indicate FGF21 as a crucial mediator in liver-pancreas crosstalk, improving lipid and glucose metabolism, enhancing pancreatic function, and potentiating the therapeutic efficacy of SGLT2i, thereby representing a target for prediabetes treatment.
Authors
- Valéry Gmyr (ORCID: https://orcid.org/0000-0003-1236-359X)
- François Pattou (ORCID: https://orcid.org/0000-0001-8388-3766)
- Chiara Saponaro (ORCID: https://orcid.org/0000-0001-7336-7362)
- Ana Acosta‐Montalvo
- Nathalie Delalleau
- Julien Thévenet (ORCID: https://orcid.org/0000-0001-6873-8640)
- Isaline Louvet (ORCID: https://orcid.org/0009-0007-8445-1157)
- Gianni Pasquetti
- Julie Kerr‐Conte (ORCID: https://orcid.org/0000-0002-7590-1896)
- Caroline Bonner (ORCID: https://orcid.org/0000-0002-4430-8280)
- Maria Moreno‐Lopez
Institutions
- Inserm (FR)
- Université de Lille (FR)
- Institut Pasteur de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1111/dom.16089
- Citations
- 1
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Eli Lilly and Company
- Université de Lille
- European Genomic Institute for Diabetes
- European Foundation for the Study of Diabetes
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale
- Société Francophone du Diabète